Cargando…
Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial
BACKGROUND: Pathogenesis in non-alcoholic steatohepatitis (NASH) involves abnormal cholesterol metabolism and hepatic accumulation of toxic free cholesterol. Apical sodium-dependent bile acid transporter (ASBT) inhibition in the terminal ileum may facilitate removal of free cholesterol from the live...
Autores principales: | Tiessen, Renger G., Kennedy, Ciara A., Keller, Bradley T., Levin, Nancy, Acevedo, Lisette, Gedulin, Bronislava, van Vliet, Andre A., Dorenbaum, Alejandro, Palmer, Melissa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756385/ https://www.ncbi.nlm.nih.gov/pubmed/29304731 http://dx.doi.org/10.1186/s12876-017-0736-0 |
Ejemplares similares
-
Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice
por: Salic, Kanita, et al.
Publicado: (2019) -
A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis
por: Palmer, Melissa, et al.
Publicado: (2018) -
Absorption, Distribution, Metabolism, and Excretion of [(14)C]-Volixibat in Healthy Men: Phase 1 Open-Label Study
por: Siebers, Nicholas, et al.
Publicado: (2017) -
Arylsulfonylamino-Benzanilides as Inhibitors of the Apical Sodium-Dependent Bile Salt Transporter (SLC10A2)
por: Liu, Hong-Tao, et al.
Publicado: (2013) -
The Beneficial Effects of Apical Sodium‐Dependent Bile Acid Transporter Inactivation Depend on Dietary Fat Composition
por: van de Peppel, Ivo P., et al.
Publicado: (2020)